| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Our lead pharmaceutical product OPAL A is in a Phase II clinical trial for the treatment of non-healing venous and pressure ulcers. OPAL A delivers highly effective wound debridement. We believe that after the required regulatory testing of the safety and efficacy of the isolated chemical entities responsible for this bioactivity a pharmaceutical drug for use in the debridement of wounds will be approved and marketed around the globe. |
| Category: | Health & biotech |
| URL: | http://www.phoenixeaglecompany.com/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2002 |
| Address: | |
| State: | Western Australia |
| Overseas Operations: | No |
| Twitter: | [twitter-timeline username=”“] |
| Facebook: | |
| Linkedin: | |
| Founders: |
No items found
|
| Awards won: | |
